These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11447433)

  • 21. Ki-67 in pituitary neoplasms: a review--part I.
    Salehi F; Agur A; Scheithauer BW; Kovacs K; Lloyd RV; Cusimano M
    Neurosurgery; 2009 Sep; 65(3):429-37; discussion 437. PubMed ID: 19687686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.
    Knosp E; Kitz K; Perneczky A
    Neurosurgery; 1989 Dec; 25(6):927-30. PubMed ID: 2601824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression.
    Widhalm G; Wolfsberger S; Preusser M; Fischer I; Woehrer A; Wunderer J; Hainfellner JA; Knosp E
    J Neurosurg; 2009 Sep; 111(3):563-71. PubMed ID: 18991501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
    Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
    J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
    Mastronardi L; Guiducci A; Puzzilli F
    BMC Cancer; 2001; 1():12. PubMed ID: 11570981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
    Gejman R; Swearingen B; Hedley-Whyte ET
    Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody.
    Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A
    Tumori; 2000; 86(3):229-32. PubMed ID: 10939604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pituitary adenomas: relationship between invasiveness and proliferative cell nuclear index].
    Tella Junior OI; Herculano MA; Delcelo R
    Arq Neuropsiquiatr; 2000 Dec; 58(4):1055-63. PubMed ID: 11105073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.
    Ekramullah SM; Saitoh Y; Arita N; Ohnishi T; Hayakawa T
    Acta Neurochir (Wien); 1996; 138(12):1449-55. PubMed ID: 9030353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical analysis of RCAS1 in human pituitary adenomas.
    Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A
    Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mdm2 and the p53 pathway in human pituitary adenomas.
    Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
    Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
    Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody.
    Pizarro CB; Oliveira MC; Coutinho LB; Ferreira NP
    Braz J Med Biol Res; 2004 Feb; 37(2):235-43. PubMed ID: 14762579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody.
    Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Maira G
    J Clin Pathol; 1999 Feb; 52(2):107-11. PubMed ID: 10396237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Invasive giant pituitary adenomas].
    Matsko DE; Vogel G; Ulitin AIu; Oliushin VE; Moes G; Pergamenshchikov AA; Burnin KS; Safarov BI; Markova NV
    Arkh Patol; 2007; 69(2):46-50. PubMed ID: 17642195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical expression of nestin in the non-tumorous hypophysis and in pituitary neoplasms.
    Rotondo F; Kovacs K; Horvath E; Bell CD; Lloyd RV; Scheithauer BW
    Acta Neuropathol; 2006 Mar; 111(3):272-7. PubMed ID: 16538520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender-related differences in non-functioning pituitary adenomas.
    Schaller B
    Neuro Endocrinol Lett; 2003 Dec; 24(6):425-30. PubMed ID: 15073569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical characteristics of duodenal adenomas in familial adenomatous polyposis with special reference to cell kinetics.
    Esaki M; Matsumoto T; Yao S; Nakamura S; Hirahashi M; Yao T; Iida M
    Hum Pathol; 2005 Jan; 36(1):66-73. PubMed ID: 15712184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma.
    Nishi T; Kuratsu J; Takeshima H; Saito Y; Kochi M; Ushio Y
    Int J Mol Med; 1999 Feb; 3(2):157-61. PubMed ID: 9917523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
    Matsuyama J
    Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.